Position in HLN
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$9,656
-$39,252 QoQ
Shares Held
1,035
-78.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#478
of 639 holders
Holding Since
Mar 2024
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Continuum Advisory, LLC holds $354,270 across 17 Drug Manufacturers - Specialty & Generic names. HLN ranks #6 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
207 | $112,158 | |
| 2 | ZTS |
Zoetis Inc.
|
1,524 | $109,514 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
418 | $70,449 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,668 | $16,680 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
491 | $16,635 | |
| 6 | HLN |
Haleon plc
This page
|
1,035 | $9,656 | |
| 7 | VTRS |
Viatris Inc
|
554 | $8,797 | |
| 8 | COLL |
Collegium Pharmaceutical, Inc
|
105 | $3,801 |
All Filings in HLN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,656 | 1,035 | Shares | Sole | 2026-08-06 | |
| 2025-03-31 | $48,908 | 4,753 | Shares | Sole | 2025-04-23 | |
| 2024-12-31 | $17,963 | 1,883 | Shares | Sole | 2025-02-18 | |
| 2024-09-30 | $19,900 | 1,881 | Shares | Sole | 2024-11-15 | |
| 2024-06-30 | $16,255 | 1,968 | Shares | Sole | 2024-07-19 | |
| 2024-03-31 | $16,708 | 1,968 | Shares | Sole | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||